scholarly journals A Model of a Novel Coronavirus Infection in Golden Syrian Hamsters: Major Pathological Changes

Biomeditsina ◽  
2021 ◽  
Vol 17 (3) ◽  
pp. 90-94
Author(s):  
S. V. Chepur ◽  
V. A. Myasnikov ◽  
M. A. Tyunin ◽  
N. S. Ilinskiy ◽  
A. S. Nikishin ◽  
...  
Keyword(s):  
Body Weight ◽  
Pathological Changes ◽  
Histopathological Changes ◽  
Syrian Hamsters ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The paper presents data on the dynamics of body weight and mass coeffi cient of lungs in golden Syrian hamsters after infection with the SARS CoV-2 virus. It was found that the most pronounced deviations of the studied parameters develop on the 7th day of the disease. The study also demonstrates the main histopathological changes in the lungs during this period of the disease.

scholarly journals Supplementation of Vitamin E Protects Chickens from Newcastle Disease Virus-Mediated Exacerbation of Intestinal Oxidative Stress and Tissue Damage

2018 ◽  
Vol 47 (4) ◽  
pp. 1655-1666 ◽  
Author(s):  
Zaib Ur Rehman ◽  
Luping Che ◽  
Shanhui Ren ◽  
Ying Liao ◽  
Xusheng Qiu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Body Weight ◽  
Vitamin E ◽  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Negative Control ◽  
Jejunal Mucosa ◽  
Pathological Changes ◽  
Histopathological Changes

Background/Aims: Newcastle disease virus (NDV) causes a highly devastating and contagious disease in poultry, which is mainly attributed to extensive tissue damages in the digestive, respiratory and nervous systems. However, nature and dynamics of NDV-induced oxidative stresses in the intestine of chickens remain elusive. Methods: In this study, we examined the magnitude of intestinal oxidative stress and histopathological changes caused by the virulent NDV infection, and explored the protective roles of vitamin E (vit. E) in ameliorating these pathological changes. For these purposes, chickens were divided into four groups namely i) non supplemented and non-challenged (negative control, CON); ii) no supplementation of vit. E but challenged with ZJ1 (positive control, NS+CHA); iii) vit. E supplementation at the dose of 50 IU/day/Kg body weight and ZJ1 challenge (VE50+CHA); and 4) vit. E supplementation at the dose of 100 IU/day/Kg body weight and ZJ1 challenge (VE100+CHA). In all groups, we analyzed concentrations of glutathione (GSH), malondialdehyde (MDA), nitric oxide (NO), total antioxidant capacity (T-AOC), and activity of glutathione S-transferase (GST), superoxide dismutase (SOD), catalase (CAT) using biochemical methods. The virus loads were determined by quantitative RT-PCR and antibody titers by hemagglutination inhibition assays. We also examined the histopathological changes in the duodenal and jejunal mucosa at 3 and 5-day post infection (dpi) with NDV. Results: A significant elevation in the NO level was observed in NDV challenged chickens compared to the CON chickens at 2 dpi. The MDA contents were significantly increased whereas GSH was significantly decreased in NDV-challenged chickens compared to control. Furthermore, activities of GST, CAT, SOD, as well as the TOAC were markedly decreased in challenged chickens in comparison with control. Virus copy numbers were higher in NDV infected NS+CHA group compared to other groups. Severe histopathological changes including inflammation, degeneration and broken villi were observed in the intestine of NDV challenged chickens. However, all these malfunctions of antioxidant system and pathological changes in the intestine were partially or completely reversed by the vit. E supplementation. Conclusions: Our results suggest that NDV infection causes oxidative stress and histopathological changes in the duodenum and jejunum of chickens, which can be partially or fully ameliorated by supplementation of vit. E. Additionally, these findings suggest that oxidative stress contributes to the intestinal damages in NDV infected chickens. These findings will help to understand the pathogenesis of NDV and further investigation of therapeutic agents for control of Newcastle disease.

Experience in Applying Hyperbaric Oxygen Therapy Using Portable Pressure Chambers for the Treatment of Patients with the Novel Coronavirus Infection COVID-19

Biomeditsina ◽  
2020 ◽  
pp. 39-46
Author(s):  
A. S. Samoilov ◽  
Yu. D. Udalov ◽  
M. V. Sheyanov ◽  
A. V. Gholinsky ◽  
A. B. Litvinenko
Keyword(s):  
Oxygen Saturation ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Capillary Blood ◽  
Blood Hemoglobin ◽  
Patient Groups ◽  
Radiological Changes ◽  
Coronavirus Infection ◽  
Novel Coronavirus

This communication presents the experience of using mobile pressure chambers in patients with the confi rmed novel coronavirus infection in hospital settings. The obtained preliminary results indicate positive antihypoxic effects of hyperbaric oxygen therapy (HBO) applied in the form of increased saturation. After a session of HBO, patients demonstrated an increase in the oxygen saturation of capillary blood hemoglobin at the average level of 3.71 points. Differences between SatO2 levels prior to and following HBO treatment were signifi cant in the CT2, CT3 and CT4 groups (p0.05). As expected, the effi cacy of HBO in terms of the oxygen saturation of capillary blood hemoglobin was the greatest in the patient groups showing pronounced clinical and radiological changes in the lungs.

Review on Efficacy of Herbal Antiviral Drugs against COVID-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1116-1121
Author(s):  
Pooja P. Thakre ◽  
Vinod Ade ◽  
Shweta Parwe
Keyword(s):  
Physical Contact ◽  
Research Articles ◽  
Herbal Drugs ◽  
Plant Origin ◽  
Respiratory Pathway ◽  
Traditional Medicines ◽  
The Past ◽  
Primary Health ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Coronavirus disease (CoViD-19) is an infection of the respiratory system caused due to various viruses affects the respiratory pathway, and it can spread from one person to another by coughing, sneezing or physical contact. Commonly include cough, cold, fever are the symptoms. Viral diseases increase worldwide concern, including emerging and chronic viruses. The invention of new anti-viral drugs from plants has implicit in the past. The Coronavirus disease 19 (COVID-19) caused due to severe acute respiratory syndrome, which is a transmittable and pathogenic viral infection. Several traditional medicines of plant origin having antimicrobial and anti-inflammatory properties some have been studied for their anti-viral properties and immune-modulating effects. Herbal drugs are now in massive requirement in the developing countries for primary health care not because of their economical but also for better civilising adequacy, improved compatibility with the human body and significantly fewer side effects. This review gives an overview of some critical traditionally used medicinal herbs with anti-viral properties—the literature regarding the drugs of this group, collected from Ayurveda classics. Research articles are collected from published material and discussed per therapeutic actions. Most of the Herbs are with Katu Rasa (pungent) and Ushna Virya (hot potency). They are indicated in diseases, viz. Kasa (cough), Shwas (asthma), Krumi (worm/ infection). Krumihara property drugs which are correlated with anti-viral action helps to prevent against Novel coronavirus infection.

Association and treatment of diabetes in patients affected by Covid-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1198-1201
Author(s):  
Syed Yasir Afaque
Keyword(s):  
Diabetes Mellitus ◽  
Prognostic Value ◽  
Heart Diseases ◽  
The Novel ◽  
The World ◽  
Treatment Of Diabetes ◽  
Coronavirus Infection ◽  
Composite Outcomes ◽  
Novel Coronavirus ◽  
The Impact

In December 2019, a unique coronavirus infection, SARS-CoV-2, was first identified in the province of Wuhan in China. Since then, it spread rapidly all over the world and has been responsible for a large number of morbidity and mortality among humans. According to a latest study, Diabetes mellitus, heart diseases, Hypertension etc. are being considered important risk factors for the development of this infection and is also associated with unfavorable outcomes in these patients. There is little evidence concerning the trail back of these patients possibly because of a small number of participants and people who experienced primary composite outcomes (such as admission in the ICU, usage of machine-driven ventilation or even fatality of these patients). Until now, there are no academic findings that have proven independent prognostic value of diabetes on death in the novel Coronavirus patients. However, there are several conjectures linking Diabetes with the impact as well as progression of COVID-19 in these patients. The aim of this review is to acknowledge about the association amongst Diabetes and the novel Coronavirus and the result of the infection in such patients.

Impact of Novel Coronavirus (COVID-19) on Pregnant Women: A Review

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Saima Habeeb ◽  
Manju Chugani
Keyword(s):  
Pregnant Women ◽  
Vertical Transmission ◽  
Respiratory Infections ◽  
Age Groups ◽  
Well Being ◽  
Fetal Outcome ◽  
Global Public Health ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
The Impact

: The novel coronavirus infection (COVID‐19) is a global public health emergency.Since its outbreak in Wuhan, China in December 2019, the infection has spread at an alarming rate across the globe and humans have been locked down to their countries, cities and homes. As of now, the virus has affected over 20million people globally and has inflicted over 7 lac deaths. Nevertheless, the recovery rate is improving with each passing day and over 14 million people have recuperated so far. The statistics indicate that nobody is immune to the disease as the virus continues to spread among all age groups; newborns to the elders, and all compartmentsincluding pregnant women. However, pregnant women may be more susceptible to this infection as they are, in general, highly vulnerable to respiratory infections. There is no evidence for vertical transmission of the COVID-19 virus among pregnant women, but an increased prevalence of preterm deliveries. Besides this, the COVID-19 may alter immune response at the maternal-fetal interface and affect the well-being of mothers as well as infants. Unfortunately, there is limited evidence available in the open literature regarding coronavirus infection during pregnancy and it now appears that certain pregnant women have infected during the present 2019-nCoV pandemic. In this short communication, we study the impact of the COVID-19 infection on vertical transmission and fetal outcome among pregnant women.

Possible benefits of reformulating antiviral drugs with nanoemulsion system in the treatment of novel coronavirus infection

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Manish Kumar ◽  
Chandra Prakash Jain
Keyword(s):  
Drug Delivery ◽  
Drug Therapy ◽  
Pulmonary Surfactant ◽  
Antiviral Drug ◽  
Treatment Strategies ◽  
Drug Dosage ◽  
Antiviral Drugs ◽  
Antiviral Action ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Background: An outbreak of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection or COVID 19, causing serious threats to all around the world. Until an effective and safe vaccine for novel coronavirus is developed by scientists, current drug therapy should by optimize for the control and treatment of COVID 19. Objective: In this manuscript, we are presenting a perspective on possible benefits of reformulating antiviral drug dosage form with nanoemulsion system against novel coronavirus infection. Methods: Literature review has been done on COVID 19, treatment strategies, novel drug delivery systems and role of pulmonary surfactant on lungs protection. Results: Nanoemulsion system and its components have certain biophysical properties which could increase the efficacy of drug therapy. Antiviral drugs, delivered through a nanoemulsion system containing P-gp inhibitor (surfactant and cosolvent), can inhibit the cellular resistance to drugs and would potentiate the antiviral action of drugs. Pulmonary surfactant (PS) assisted antiviral drug delivery by nanoemulsion system could be another effective approach for the treatment of COVID 19. Use of functional excipients like pulmonary surfactant (PS) and surfactant proteins (SPs), in the formulation of the antiviral drug-loaded nanoemulsion system can improve the treatment of coronavirus infection. Conclusion: In our opinion for synergizing antiviral action, lipid and protein portion of PS and their commercial analogs should be explored by pharmaceutical scientists to use them as a functional excipient in the formulation of antiviral drugloaded nanoemulsion system.

scholarly journals An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Anupama M. Gudadappanavar ◽  
Jyoti Benni
Keyword(s):  
Antiviral Drug ◽  
Drug Repurposing ◽  
Respiratory Illness ◽  
World Health ◽  
Recombinant Vaccines ◽  
Subunit Vaccines ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Full Length Genome

AbstractA novel coronavirus infection coronavirus disease 2019 (COVID-19) emerged from Wuhan, Hubei Province of China, in December 2019 caused by SARS-CoV-2 is believed to be originated from bats in the local wet markets. Later, animal to human and human-to-human transmission of the virus began and resulting in widespread respiratory illness worldwide to around more than 180 countries. The World Health Organization declared this disease as a pandemic in March 2020. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. Nevertheless, few broad-spectrum antiviral drugs have been studied against COVID-19 in clinical trials with clinical recovery. In the current review, we summarize the morphology and pathogenesis of COVID-19 infection. A strong rational groundwork was made keeping the focus on current development of therapeutic agents and vaccines for SARS-CoV-2. Among the proposed therapeutic regimen, hydroxychloroquine, chloroquine, remdisevir, azithromycin, toclizumab and cromostat mesylate have shown promising results, and limited benefit was seen with lopinavir–ritonavir treatment in hospitalized adult patients with severe COVID-19. Early development of SARS-CoV-2 vaccine started based on the full-length genome analysis of severe acute respiratory syndrome coronavirus. Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline. This article concludes and highlights ongoing advances in drug repurposing, therapeutics and vaccines to counter COVID-19, which collectively could enable efforts to halt the pandemic virus infection.

Sign in / Sign up

Export Citation Format

Share Document